Canada’s Strategic Innovation Fund has awarded up to C$56M to VBI Vaccines (NASDAQ:VBIV) to support the development of its COVID-19 vaccine program VBI-2900 through Phase 2.
The company is currently collaborating with the National Research Council of Canada on preclinical studies aimed at selecting the best candidate for clinical trials, expected to start by year-end.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.